Aiming, I picked up some additional Cortex today, couldn't resist :o) Even if there's more weakness, the current price range looks cheap, all things considered. I'm figuring we'll conservatively see the $4-5 range once the IND is filed and approved.
The problem with waiting for the IND to be filed before buying is that Cortex will hear from Neurology prior to the filing, once Neurology has finished their full evaluation of the tox data. That event could generate another press release, clearly confirming what was suggested in the 7-17 press release (broad dosing liberalization), and then it's off to the races. Or, that confirmation will be contained in the IND filing press release itself, with the same strong effect on the share price.
Either way, I think Dr. Tracy's analysis will turn out to be correct - that in the current ultraconservative regulatory climate, Neurology wouldn't have allowed higher doses in the AD PET trial unless they were strongly leaning toward dosing liberalization all around. If they had doubts they would have waited, but instead they liberalized, and that's a strong signal. As we know, it was the hardnosed tox head at Neurology who originally initiated the clinical hold and dosing limitations, and it appears that we've won him over.
AI
Market Data 
Markets 
